Your browser is no longer supported. Please, upgrade your browser.
Settings
CGEM [NASD]
Cullinan Oncology, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own0.80% Shs Outstand43.30M Perf Week-11.16%
Market Cap913.28M Forward P/E- EPS next Y-1.98 Insider Trans-69.15% Shs Float35.54M Perf Month-6.17%
Income-53.90M PEG- EPS next Q-0.42 Inst Own74.20% Short Float7.30% Perf Quarter-11.37%
Sales18.90M P/S48.32 EPS this Y-150.80% Inst Trans0.03% Short Ratio10.89 Perf Half Y-29.89%
Book/sh10.52 P/B2.11 EPS next Y-52.30% ROA-17.20% Target Price- Perf Year-
Cash/sh8.19 P/C2.71 EPS next 5Y- ROE-27.60% 52W Range20.35 - 59.85 Perf YTD-25.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.89% Beta-
Dividend %- Quick Ratio60.00 Sales past 5Y- Gross Margin- 52W Low9.14% ATR1.63
Employees24 Current Ratio60.00 Sales Q/Q- Oper. Margin- RSI (14)43.39 Volatility8.64% 6.86%
OptionableYes Debt/Eq0.00 EPS Q/Q-10.00% Profit Margin- Rel Volume0.56 Prev Close23.42
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume238.35K Price22.21
Recom1.70 SMA20-4.39% SMA50-14.30% SMA200-29.98% Volume132,433 Change-5.17%
Apr-27-21Upgrade Morgan Stanley Equal-Weight → Overweight $40
Feb-02-21Initiated SVB Leerink Outperform $52
Feb-02-21Initiated Morgan Stanley Equal-Weight $38
Feb-02-21Initiated Evercore ISI Outperform $55
Feb-01-21Initiated H.C. Wainwright Buy $47
Oct-18-21 07:00AM  
Sep-08-21 04:01PM  
Aug-16-21 06:44AM  
Aug-10-21 06:30AM  
Aug-05-21 04:05PM  
Jul-19-21 07:56PM  
Jun-29-21 08:00AM  
Jun-07-21 10:57AM  
09:26AM  
08:30AM  
Jun-04-21 11:53AM  
09:00AM  
May-21-21 08:00AM  
May-19-21 05:00PM  
May-14-21 06:30AM  
Apr-08-21 01:38AM  
Apr-07-21 10:08AM  
Mar-30-21 06:15AM  
Mar-02-21 09:48AM  
Feb-22-21 07:30AM  
Jan-12-21 09:43PM  
Jan-08-21 12:13AM  
Jan-07-21 09:03PM  
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Michaelson JenniferSee RemarksOct 18Option Exercise4.304,00017,20026,911Oct 20 04:30 PM
Michaelson JenniferSee RemarksOct 18Sale21.424,00085,66922,911Oct 20 04:30 PM
Trigilio JeffreyChief Financial OfficerOct 15Option Exercise4.308,00034,40010,250Oct 18 04:15 PM
Zawel LeighSee RemarksOct 15Sale25.0019,574489,35037,285Oct 18 04:15 PM
Trigilio JeffreyChief Financial OfficerOct 15Sale25.008,000200,0002,250Oct 18 04:15 PM
Zawel LeighSee RemarksOct 07Sale25.001,07926,97556,859Oct 12 04:30 PM
Michaelson JenniferSee RemarksSep 20Option Exercise4.304,00017,20026,911Sep 21 04:30 PM
Zawel LeighSee RemarksSep 20Sale25.167,468187,89557,938Sep 21 04:30 PM
Michaelson JenniferSee RemarksSep 20Sale24.514,00098,04822,911Sep 21 04:30 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 16Sale29.063,12490,7837,648,268Sep 20 05:31 PM
GADICKE ANSBERTDirectorSep 16Sale29.063,12490,7837,648,268Sep 20 05:30 PM
GADICKE ANSBERTDirectorSep 16Sale29.0643212,554244,551Sep 20 05:30 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 15Sale29.166,425187,3537,651,392Sep 16 04:45 PM
GADICKE ANSBERTDirectorSep 15Sale29.166,425187,3537,651,392Sep 16 04:44 PM
GADICKE ANSBERTDirectorSep 15Sale29.1688825,894244,983Sep 16 04:44 PM
GADICKE ANSBERTDirectorSep 14Sale29.177,106207,2827,657,817Sep 16 04:44 PM
GADICKE ANSBERTDirectorSep 14Sale29.1798228,645245,871Sep 16 04:44 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 14Sale29.177,106207,2827,657,817Sep 16 04:45 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 13Sale29.103,595104,6147,664,923Sep 13 06:24 PM
GADICKE ANSBERTDirectorSep 13Sale29.103,595104,6147,664,923Sep 13 06:22 PM
GADICKE ANSBERTDirectorSep 13Sale29.1049714,463246,853Sep 13 06:22 PM
GADICKE ANSBERTDirectorSep 10Sale29.045,931172,2367,668,518Sep 13 06:22 PM
GADICKE ANSBERTDirectorSep 10Sale29.0482023,813247,350Sep 13 06:22 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 10Sale29.045,931172,2367,668,518Sep 13 06:24 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 09Sale29.3513,727402,8877,674,449Sep 13 06:24 PM
GADICKE ANSBERTDirectorSep 09Sale29.3513,727402,8877,674,449Sep 13 06:22 PM
GADICKE ANSBERTDirectorSep 09Sale29.351,89855,706248,170Sep 13 06:22 PM
Trigilio JeffreyChief Financial OfficerSep 08Option Exercise4.3015,00064,50017,250Sep 09 04:15 PM
Baeuerle PatrickSee RemarksSep 08Option Exercise4.3011,00047,30011,000Sep 09 04:15 PM
Baeuerle PatrickSee RemarksSep 08Sale28.4511,000312,9500Sep 09 04:15 PM
Trigilio JeffreyChief Financial OfficerSep 08Sale28.4815,000427,1532,250Sep 09 04:15 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 08Sale29.1110,842315,6117,688,176Sep 08 06:20 PM
GADICKE ANSBERTDirectorSep 08Sale29.1110,842315,6117,688,176Sep 08 06:17 PM
GADICKE ANSBERTDirectorSep 08Sale29.111,49943,636250,068Sep 08 06:17 PM
Zawel LeighSee RemarksSep 07Sale28.9528,118814,01665,406Sep 08 04:15 PM
GADICKE ANSBERTDirectorSep 07Sale29.0425,067727,9467,699,018Sep 08 06:17 PM
GADICKE ANSBERTDirectorSep 07Sale29.043,465100,624251,567Sep 08 06:17 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 07Sale29.0425,067727,9467,699,018Sep 08 06:20 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 03Sale29.6012,731376,8387,724,085Sep 08 06:20 PM
GADICKE ANSBERTDirectorSep 03Sale29.6012,731376,8387,724,085Sep 08 06:17 PM
GADICKE ANSBERTDirectorSep 03Sale29.601,76052,096255,032Sep 08 06:17 PM
GADICKE ANSBERTDirectorSep 02Sale29.4615,757464,2017,736,816Sep 02 05:25 PM
GADICKE ANSBERTDirectorSep 02Sale29.462,17864,164256,792Sep 02 05:25 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 02Sale29.4615,757464,2017,736,816Sep 02 05:26 PM
UBS Oncology Impact Fund L.P.10% OwnerSep 01Sale29.475,714168,3927,752,573Sep 02 05:26 PM
GADICKE ANSBERTDirectorSep 01Sale29.475,714168,3927,752,573Sep 02 05:25 PM
GADICKE ANSBERTDirectorSep 01Sale29.4779023,281258,970Sep 02 05:25 PM
GADICKE ANSBERTDirectorAug 31Sale29.822,83884,6257,758,287Sep 02 05:25 PM
GADICKE ANSBERTDirectorAug 31Sale29.8239211,689259,760Sep 02 05:25 PM
UBS Oncology Impact Fund L.P.10% OwnerAug 31Sale29.822,83884,6257,758,287Sep 02 05:26 PM
UBS Oncology Impact Fund L.P.10% OwnerAug 30Sale29.3031,001908,3297,761,125Aug 31 04:47 PM
GADICKE ANSBERTDirectorAug 30Sale29.3031,001908,3297,761,125Aug 31 04:48 PM
GADICKE ANSBERTDirectorAug 30Sale29.304,285125,550260,152Aug 31 04:48 PM
GADICKE ANSBERTDirectorAug 27Sale29.0913,357388,5557,792,126Aug 31 04:48 PM
GADICKE ANSBERTDirectorAug 27Sale29.091,84653,700264,437Aug 31 04:48 PM
UBS Oncology Impact Fund L.P.10% OwnerAug 27Sale29.0913,357388,5557,792,126Aug 31 04:47 PM
GADICKE ANSBERTDirectorAug 25Sale29.091,71349,8317,805,483Aug 25 07:41 PM
GADICKE ANSBERTDirectorAug 25Sale29.092376,894266,283Aug 25 07:41 PM
UBS Oncology Impact Fund L.P.10% OwnerAug 25Sale29.091,71349,8317,805,483Aug 25 07:42 PM
UBS Oncology Impact Fund L.P.10% OwnerAug 24Sale29.4850,8221,498,2337,807,196Aug 25 07:42 PM
GADICKE ANSBERTDirectorAug 24Sale29.4850,8821,500,0017,807,196Aug 25 07:41 PM
GADICKE ANSBERTDirectorAug 24Sale29.487,025207,097266,520Aug 25 07:41 PM
GADICKE ANSBERTDirectorAug 23Sale29.1153,3591,553,2807,858,018Aug 25 07:41 PM
GADICKE ANSBERTDirectorAug 23Sale29.117,376214,715273,545Aug 25 07:41 PM
UBS Oncology Impact Fund L.P.10% OwnerAug 23Sale29.1153,3591,553,2807,858,018Aug 25 07:42 PM
Zawel LeighSee RemarksAug 23Sale29.0028,118815,42293,524Aug 24 04:06 PM
Michaelson JenniferSee RemarksAug 18Option Exercise4.304,00017,20026,911Aug 24 04:06 PM
Michaelson JenniferSee RemarksAug 18Sale27.664,000110,64822,911Aug 24 04:06 PM
UBS Oncology Impact Fund L.P.10% OwnerAug 11Sale29.052,51072,9167,911,377Aug 12 04:55 PM
GADICKE ANSBERTDirectorAug 11Sale29.052,51072,9167,911,377Aug 12 04:54 PM
GADICKE ANSBERTDirectorAug 11Sale29.0534710,080280,921Aug 12 04:54 PM
Baeuerle PatrickSee RemarksAug 10Option Exercise4.3011,00047,30011,000Aug 26 07:11 PM
Baeuerle PatrickSee RemarksAug 10Sale27.0011,000297,0000Aug 26 07:11 PM
Zawel LeighSee RemarksAug 10Sale27.416,914189,517121,642Aug 11 04:15 PM
Zawel LeighSee RemarksAug 09Sale26.5721,204563,333128,556Aug 11 04:15 PM